3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trametinib
2
dabrafenib
2
Palliative Care
2
Nivolumab
2
Methods
2
Ipilimumab
2
CTLA-4 Antigen
2
Biopsy
2
varlilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
ripretinib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
peginterferon alfa-2a
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
bemcentinib
×
Other hematologic neoplasm
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts